http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 08:02:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/ACURX+drug+research+presented+at+Leiden+conference/26650786.html <p>Acurx Pharmaceuticals (NASDAQ: ACXP) announced that research from its collaboration with Leiden University Medical Center (LUMC) in the Netherlands was presented at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference on June 11, 2026.</p><p>The presentation, delivered by Mia Urem, PhD, from LUMC, was titled "A unique inhibitor conformation selectively targets Gram+ Bacterial DNA Replication." It detailed findings on ibezapolstat, Acurx's lead antibiotic candidate, and related compounds that target Gram-positive bacteria.</p><p>Using high-resolution cryo-electron microscopy, Dr. Urem's group resolved the structure of ibezapolstat in relation to the binding pocket of a Gram-positive DNA polymerase IIIC (pol IIIC) to a resolution http://www.streetinsider.com/Corporate+News/ACURX+drug+research+presented+at+Leiden+conference/26650786.html Tue, 16 Jun 2026 08:02:17 -0400 ACXP http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html <div class="xn-content"> <ul type="disc"><li>Results are from Acurx's ongoing scientific collaboration with <span>Leiden University Medical Center</span> (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors</li><li>LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues specifically target Gram-positive bacteria</li><li>High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å</li><li>The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), with a development program for post-exposure prophylaxis http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Announces+Presentation+of+Results+from+Leiden+University+Medical+Center+Public-Private+Partnership+for+Its+DNA+pol+IIIC+Inhibitors+at+the+Leiden+Early+Drug+Discovery+%26amp%3B+Develo/26650688.html Tue, 16 Jun 2026 08:00:00 -0400 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+%28NASDAQ%3A+ACXP%29+Highlights+FDA%27s+New+CDI+Guidance+That+Could+Accelerate+Approval+Path+for+Ibezapolstat/26519791.html <p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 19, 2026 / </strong>New to The Street's longtime featured biotechnology client, <a rel="nofollow" href="https://pr.report/lomt">Acurx Pharmaceuticals, Inc.</a> (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies developing therapies targeting Clostridioides difficile infection (CDI), as the U.S. Food and Drug Administration finalized updated guidance that may significantly streamline the path toward approval for new CDI antibiotics.</p><div style="margin:20px auto;width:600px;" data-aw="video" blockindent="auto"><div data-oembed-url="https://youtu.be/40Pdben8O4o?si=hMzjPm35b3ZOH6RE"><div style="position: relative; padding-bottom: 100%; height: 0; padding-bottom: 56.2493%;"><iframe src="https://www.youtube.com/embed/40Pdben8O4o" style="position: absolute; width: 100%; height: 100%; top: 0; left: 0;" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen=""></iframe><img width="0" http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+%28NASDAQ%3A+ACXP%29+Highlights+FDA%27s+New+CDI+Guidance+That+Could+Accelerate+Approval+Path+for+Ibezapolstat/26519791.html Tue, 19 May 2026 12:25:00 -0400 ACXP http://www.streetinsider.com/ACCESS+Newswire/Acurx+Pharmaceuticals+%28NASDAQ%3A+ACXP%29+Highlights+FDA%27s+New+CDI+Guidance+That+Could+Accelerate+Approval+Path+for+Ibezapolstat/26519791.html <p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 19, 2026 / </strong>New to The Street's longtime featured biotechnology client, <a rel="nofollow" href="https://pr.report/lomt">Acurx Pharmaceuticals, Inc.</a> (Nasdaq:ACXP), highlighted a potentially transformative regulatory development for companies developing therapies targeting Clostridioides difficile infection (CDI), as the U.S. Food and Drug Administration finalized updated guidance that may significantly streamline the path toward approval for new CDI antibiotics.</p><div style="margin:20px auto;width:600px;" data-aw="video" blockindent="auto"><div data-oembed-url="https://youtu.be/40Pdben8O4o?si=hMzjPm35b3ZOH6RE"><div style="position: relative; padding-bottom: 100%; height: 0; padding-bottom: 56.2493%;"><iframe src="https://www.youtube.com/embed/40Pdben8O4o" style="position: absolute; width: 100%; height: 100%; top: 0; left: 0;" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen=""></iframe><img width="0" http://www.streetinsider.com/ACCESS+Newswire/Acurx+Pharmaceuticals+%28NASDAQ%3A+ACXP%29+Highlights+FDA%27s+New+CDI+Guidance+That+Could+Accelerate+Approval+Path+for+Ibezapolstat/26519791.html Tue, 19 May 2026 12:25:00 -0400 ACXP http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477062.html si-local-file:///var/storage/secattach/20260512/26477062.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477062.html Tue, 12 May 2026 15:05:00 -0400 ACXP O.51068808 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477062.html si-local-file:///var/storage/secattach/20260512/26477062.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477062.html Tue, 12 May 2026 15:05:00 -0400 ACXP O.51068808 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477049.html si-local-file:///var/storage/secattach/20260512/26477049.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477049.html Tue, 12 May 2026 15:04:00 -0400 ACXP O.51068808 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477049.html si-local-file:///var/storage/secattach/20260512/26477049.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Acurx+Pharmaceuticals%2C+++++++++++++++/26477049.html Tue, 12 May 2026 15:04:00 -0400 ACXP O.51068808 http://www.streetinsider.com/Earnings/Acurx+Pharmaceuticals+%28ACXP%29+Misses+Q1+EPS+by+62c/26473922.html <p>Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q1 EPS of ($0.62).</p><p>For earnings history and earnings-related data on Acurx Pharmaceuticals (ACXP) <a href="http://www.streetinsider.com/ec_earnings.php?q=ACXP">click here</a>.</p> http://www.streetinsider.com/Earnings/Acurx+Pharmaceuticals+%28ACXP%29+Misses+Q1+EPS+by+62c/26473922.html Tue, 12 May 2026 08:44:04 -0400 ACXP http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended <chron>March 31, 2026</chron>.  </p> <p>Highlights of the first quarter ended <chron>March 31, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>February 2026</chron>, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html Tue, 12 May 2026 07:01:00 -0400 A.06822034 A.14320728 A.50201572 ACXP O.12478371 O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended <chron>March 31, 2026</chron>.  </p> <p>Highlights of the first quarter ended <chron>March 31, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>February 2026</chron>, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html Tue, 12 May 2026 07:01:00 -0400 A.06822034 A.14320728 A.50201572 ACXP O.12478371 O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended <chron>March 31, 2026</chron>.  </p> <p>Highlights of the first quarter ended <chron>March 31, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>February 2026</chron>, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html Tue, 12 May 2026 07:01:00 -0400 A.06822034 A.14320728 A.50201572 ACXP O.12478371 O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended <chron>March 31, 2026</chron>.  </p> <p>Highlights of the first quarter ended <chron>March 31, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>February 2026</chron>, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html Tue, 12 May 2026 07:01:00 -0400 A.06822034 A.14320728 A.50201572 ACXP O.12478371 O.20026344 O.20250741 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>May 12, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended <chron>March 31, 2026</chron>.  </p> <p>Highlights of the first quarter ended <chron>March 31, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>February 2026</chron>, we announced that the USPTO granted a new patent for our DNA pol IIIC inhibitors covering composition of matter and method of use. This patent extends to http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+First+Quarter+2026+results+and+Provides+Business+Update/26472790.html Tue, 12 May 2026 07:01:00 -0400 A.06822034 A.14320728 A.50201572 ACXP O.12478371 O.20026344 O.20250741 O.51068808